However, the microdystrophin product is less effective functionally at complementing dystrophin deficiency than is the full-length cDNA, which is also a shortcoming of AAV-vector-mediated gene delivery for DMD. The gene discussed is DMD; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.